Satellos Bioscience (NASDAQ:MSLE) Upgraded at Zacks Research

Zacks Research upgraded shares of Satellos Bioscience (NASDAQ:MSLE) to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

Satellos Bioscience Stock Down 3.2%

Shares of NASDAQ MSLE opened at $11.27 on Tuesday. The firm has a market capitalization of $174.23 million, a P/E ratio of -9.39 and a beta of 1.15. Satellos Bioscience has a one year low of $4.53 and a one year high of $12.50.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.